Voyager Acquisition Secures Final Approval for Veraxa Biotech Merger
summarizeSummary
Voyager Acquisition Corp. has announced the formal approval of its business combination with Veraxa Biotech. This critical development follows earlier reports of individual shareholder approvals, with Veraxa Biotech shareholders giving their consent on February 27 and Voyager Acquisition Corp. shareholders overwhelmingly approving the combination on March 11. The overall approval of the business combination is a significant milestone for the SPAC, indicating that all necessary conditions have been met and the deal is on track to close. This reduces uncertainty surrounding the merger and paves the way for the combined entity to begin trading. Traders should now monitor for the definitive closing date and the anticipated ticker change.
At the time of this announcement, VACH was trading at $12.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $347.9M. The 52-week trading range was $9.24 to $14.08. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.